Moreover, Plebanski’s group reported that, in acute myeloid leukemia (AML) patients, combination therapy with lenalidomide and a demethylating agent, azacitidine, downregulated TNFR2 expression on CD4 T cells and reduced the number of TNFR2+ Tregs, resulting in enhanced effector immune function (13). Here, CD4 is linked to acute myeloid leukemia.